Hepatitis A, B, and C Prevention Programs
Information and Programs for People at Risk
 
  Home
  Hep Express archives
    Search
 

Prevention Programs

  APIA programs
  Corrections, adult
  Corrections, juvenile
  Family planning
  Harm reduction
  Homeless programs
  MSM
  Perinatal related
  School programs
  STD/HIV
  Other programs
  Index of programs
    Support Group Info
  Hepatitis B
  Hepatitis C
  Listed by state
    Hepatitis B Info
  FAQ about hep B
  VISs
  Laws and mandates
  Case histories
  Photos
  Videos
    Hepatitis A Info
  FAQ about hep A
  VISs
  Laws and mandates
  Case histories
  Photos
    Hep-related Topics
  International adoption
  Tattooing and piercing
  Travel vaccination
  Healthcare workers
  Needle safety
  Dialysis
    Other Information
  CDC website
  Hep organizations
  NASTAD website
  Contact NASTAD
  About NASTAD
  Privacy policy
 

(click on the image)


Hep Express Issue

ABBREVIATIONS: ACIP, Advisory Committee on Immunization Practices; CDC, Centers for Disease Control and Prevention; DVH, Division of Viral Hepatitis; HAV, hepatitis A virus; HBV, hepatitis B virus; HCV, hepatitis C virus; IAC, Immunization Action Coalition; IDU, injection drug user; MMWR, Morbidity and Mortality Weekly Report; MSM, men who have sex with men; STD, sexually transmitted disease; VIS, Vaccine Information Statement; WHO, World Health Organization.
----------------------------------------------------------------

(1 of 9)
December 2, 2005
VISIT IAC'S BOOTH AT THE NATIONAL VIRAL HEPATITIS PREVENTION
CONFERENCE NEXT WEEK!

IAC will be hosting a booth at the National Viral Hepatitis
Prevention Conference in Washington, DC, next week. Please stop
by and introduce yourself--we would love to meet our Hep Express
subscribers. We look forward to receiving feedback on our
electronic newsletters, websites, and resource materials. We get
some of our best ideas from our readers!
---------------------------------------------------------------- 

Return to top

(2 of 9)
December 2, 2005
RIBAVIRIN PREGNANCY REGISTRY ESTABLISHED

A Ribavirin Pregnancy Registry has been established to monitor pregnancy exposures to ribavirin. The registry is a voluntary, largely prospective registry designed to collect observational data on pregnancies and outcomes following a pregnancy exposure to ribavirin. The registry also collects retrospective information, i.e., reports after the outcome of the pregnancy is known. Ribovirin exposure may be direct, through the pregnant woman or indirect, through her male sexual partner.

Ribavirin, a nucleoside analog, is indicated in combination with alpha interferon or pegylated alpha interferon for the treatment of chronic hepatitis C virus infection (HCV). The incidence of HCV infection is highest in the population with reproductive potential (2545 years of age). Therefore, it is possible that pregnancy exposure may occur during or following HCV treatment with ribavirin. It has been shown that significant teratogenic and/or embryocidal effects occurred in all animal species exposed to ribavirin; there are no data to determine if this is also the case in humans. However, ribavirin has been given an FDA Pregnancy Category X, indicating that it should not be used in women who are pregnant.

The registry will accept reports of pregnancy exposures to ribavirin from healthcare professionals, pregnant patients, or pregnant patients' male sexual partners. Exposures of interest to the registry are those occurring during pregnancy or up to six months before conception. For more information, go to: http://www.ribavirinpregnancyregistry.com/index.htm
----------------------------------------------------------------

Return to top

(3 of 9)
December 2, 2005
MULTI-CENTER TREATMENT TRIAL FOR CHILDREN WITH CHRONIC HCV NOW ENROLLING PATIENTS

PEDS C is a multi-center antiviral treatment trial for children with chronic hepatitis C, ages 518 years. The purpose of the trial is to determine if pegylated interferon alone will be as effective as pegylated interferon plus ribavirin. The basis for this study design is that children respond well to inteferon-based therapy alone and ribavirn may cause birth defects. In addition to looking at response to therapy, the study will also investigate the effect of therapy on body composition and growth and health-related quality of life.

Eleven centers in the United States are currently enrolling patients. Please check the following websites for details and contact information: http://www.PEDSC.org and http://www.clinicaltrials.gov (type in Pediatric HCV.)
----------------------------------------------------------------

Return to top

(4 of 9)
December 2, 2005
IAC REVISES MANY PRINT PIECES

IAC recently revised a dozen print pieces in response to the votes ACIP members took at their meeting in October and new FDA vaccine approvals.

Updated pieces include the following:

  1. Summary of Recommendations for Childhood and Adolescent Immunization
  2. Screening Questionnaire for Child and Teen Immunization
  3. Screening Questionnaire for Adult Immunization
  4. Screening Questionnaire for Intranasal Influenza Vaccination
  5. Notification of Vaccination Letter
  6. Temperature Log for Vaccines (Fahrenheit)
  7. Temperature Log for Vaccines (Celsius)
  8. Administering Vaccines: Dose, Route, Site, and Needle Size
  9. Vaccines and Related Products Distributed in the United States
  10. Interim VIS for meningococcal vaccine (dated 10/7/05) in Turkish
  11. September 2005 version of the Summary of Recommendations for Childhood and Adolescent Immunization in Turkish
  12. Should You be Tested for Hepatitis C? A Screening Questionnaire for Adults in Turkish

(1) Summary of Recommendations for Childhood and Adolescent Immunization (three pages) has updated information about tetanus-diphtheria-acellular-pertussis vaccine (Tdap) and hepatitis A vaccine.

To access a ready-to-print (PDF) version of it, go to:
http://www.immunize.org/catg.d/rules1.pdf

To access a web-text (HTML) version, go to:
http://www.immunize.org/nslt.d/n17/rules1.htm

(2) Screening Questionnaire for Child and Teen Immunization (two pages) has updated information on three vaccines that protect against tetanus, diphtheria, and pertussis (DTP, DTaP, Tdap) and on intranasal live attenuated influenza vaccine (LAIV). In addition, the introduction was changed.

To access a ready-to-print (PDF) version of it, go to:
http://www.immunize.org/catg.d/p4060scr.pdf

To access a web-text (HTML) version, go to:
http://www.immunize.org/catg.d/p4060scr.htm

(3) Screening Questionnaire for Adult Immunization (two pages) has updated information on intranasal live attenuated influenza vaccine (LAIV). Also, the introduction was changed.

To access a ready-to-print (PDF) version of it, go to:
http://www.immunize.org/catg.d/p4065scr.pdf

To access a web-text (HTML) version, go to:
http://www.immunize.org/catg.d/p4065scr.htm

(4) Screening Questionnaire for Intranasal Influenza Vaccination (two pages) has updated information on intranasal live attenuated influenza vaccine (LAIV). Also, the introduction was changed.

To access a ready-to-print (PDF) version of it, go to:
http://www.immunize.org/catg.d/p4067.pdf

To access a web-text (HTML) version, go to:
http://www.immunize.org/catg.d/p4067.htm

(5) Notification of Vaccination Letter (one page) has updated information on tetanus-diphtheria-acellular pertussis vaccine (Tdap), measles-mumps-rubella-varicella vaccine (MMRV), and intranasal live attenuated influenza vaccine (LAIV). In addition, the document was completely reformatted.

To access a ready-to-print (PDF) version of it, go to:
http://www.immunize.org/catg.d/p3060not.pdf

No web-text (HTML) version is available.

(6) Minor changes were made to the Temperature Log for Vaccines (Fahrenheit; four pages).

To access a ready-to-print (PDF) version of it, go to:
http://www.immunize.org/catg.d/p3039.pdf

No web-text (HTML) version is available.

(7) Minor changes were made to the Temperature Log for Vaccines (Celsius; four pages).

To access a ready-to-print (PDF) version of it, go to:
http://www.immunize.org/news.d/celsius.pdf

No web-text (HTML) version is available.

(8) Administering Vaccines: Dose, Route, Site, and Needle Size now includes information about ProQuad, the newly licensed measles-mumps-rubella-varicella vaccine.

To access a ready-to-print (PDF) version of it, go to:
http://www.immunize.org/catg.d/p3085.pdf

To access a web-text (HTML) version, go to:
http://www.immunize.org/catg.d/p3085.htm
 
(9) Vaccines and Related Products Distributed in the United States has been updated with current information on all vaccines and biologics distributed in the United States.

To access a ready-to-print (PDF) version of it, go to:
http://www.immunize.org/catg.d/2019prod.pdf

No web-text (HTML) version is available.

(10) Interim VIS for meningococcal vaccine (dated 10/7/05) in Turkish

To access a ready-to-print (PDF) version of the interim VIS for meningococcal vaccine in Turkish (dated 10/7/05), go to:
http://www.immunize.org/vis/tu_men05.pdf

To access a ready-to-print (PDF) version of it in English, go
to: http://www.immunize.org/vis/menin05.pdf

For information about the use of VISs, and for VISs in a total of 33 languages, visit IAC's VIS web section at http://www.immunize.org/vis

(11) September 2005 version of the Summary of Recommendations for Childhood and Adolescent Immunization in Turkish

Note: The current English-language version of the summary is dated November 2005. The most recent Turkish-language version is not current; the information it contains was updated in September 2005.

To access a ready-to-print (PDF) version of the Summary of Recommendations for Childhood and Adolescent Immunization in Turkish, go to:
http://www.immunize.org/catg.d/p2010tu.pdf

No web-text (HTML) version is available in Turkish.

To access a ready-to-print (PDF) version of the summary in English (dated 11/05), go to:
http://www.immunize.org/catg.d/rules1.pdf

To access a web-text (HTML) version of it in English, go to:
http://www.immunize.org/nslt.d/n17/rules1.htm

(12) Should You be Tested for Hepatitis C? A Screening Questionnaire for Adults in Turkish

To access a ready-to-print (PDF) version of the questionnaire in Turkish (dated 10/05), go to:
http://www.immunize.org/catg.d/p2192tu.pdf

No web-text (HTML) version is available in Turkish.

To access a ready-to-print (PDF) version of the questionnaire in English (dated 10/05), go to:
http://www.immunize.org/catg.d/2192hepc.pdf

To access a web-text (HTML) version of it, go to:
http://www.immunize.org/catg.d/2192hepc.htm
---------------------------------------------------------------

Return to top

(5 of 9)
December 2, 2005
NEW: IAC WEBSITE PRESENTS STANDING ORDERS PROTOCOLS IN A SINGLE TABLE FOR EASY REFERENCE

[The following is cross posted from the Immunization Action Coalition's "IAC EXPRESS" electronic newsletter, 11/28/05.]

IAC recently organized links to all its standing orders protocols into one table. The table gives website users easy access to the standing orders.

The table includes links to standing orders for administering the following vaccines to adults: influenza, pneumococcal, hepatitis B, hepatitis A, tetanus-diphtheria, measles-mumps-rubella, varicella, and meningococcal. It also includes links to a protocol for medical management of vaccine reactions in adults.

In addition, the table includes a standing orders protocol for administering influenza vaccine to children and adolescents.

To access the table, go to:
http://www.immunize.org/standingorders

You can also access the table from IAC's homepage by going to http://www.immunize.org and scrolling down the Favorites listing in the left column until you reach the entry for standing orders.
----------------------------------------------------------------

Return to top

(6 of 9)
December 2, 2005
CDC'S SATELLITE BROADCAST/WEBCAST ON SURVEILLANCE OF VACCINE-PREVENTABLE DISEASES IS SET FOR DECEMBER 8

[The following is cross posted from the Immunization Action Coalition's "IAC EXPRESS" electronic newsletter, 11/14/05.]

The CDC course Surveillance of Vaccine-Preventable Diseases will be broadcast and webcast on December 8 from 12 noon to 3:30PM ET. The course is intended only for public health professionals with responsibility for surveillance and case investigation of vaccine-preventable diseases. Individual registration will begin November 17.

Faculty includes William Atkinson, MD, MPH; John Moran, MD, MPH; Jane Seward, MBBS, MPH; and Sandra Roush, MPH. All are with NIP/CDC. A live Q&A session will allow participants nationwide to interact with course instructors by phone, fax, and email.

For comprehensive course information, go to: http://www.phppo.cdc.gov/PHTN/VPD-05 Questions about the course are being taken by email at nipinfo@cdc.gov

To register online, go to: http://www2a.cdc.gov/phtnonline Registration questions are being taken by phone at (800) 418-7246 and by email at ce@cdc.gov
---------------------------------------------------------------

Return to top

(7 of 9)
December 2, 2005
NEW: PREPUBLICATION COPIES OF THE NINTH EDITION OF THE PINK BOOK NOW AVAILABLE FOR ORDER

[The following is cross posted from the Immunization Action Coalition's "IAC EXPRESS" electronic newsletter, 11/14/05.]

The ninth edition of the Pink Book (officially titled Epidemiology and Prevention of Vaccine-Preventable Diseases) will be available February 2006. The price is $25 for prepublication orders received by January 8, 2006. After January 8, the price increases to $29.

The Pink Book is developed and published by NIP/CDC and distributed by the Public Health Foundation. It provides physicians, nurses, pharmacists, and other public health and healthcare professionals with comprehensive vaccine information and recommendations, including the following:

  • General recommendations on immunizations including timing and spacing of vaccines
  • Screening for contraindications and precautions such as pregnancy and HIV infection
  • Specific strategies to achieve high vaccine coverage
  • Vaccine safety information

Information on the following is included in the ninth edition:

  • Pertussis (to reflect licensure of Tdap vaccine [tetanus-diphtheria-acellular pertussis] and recommendations for its use)
  • Meningococcal (to reflect licensure of conjugate vaccine and recommendations for its use)
  • Hepatitis A (to reflect the universal recommendation for children 12-23 months and reduction of the minimum age from two years to 12 months).
  • Measles, mumps, rubella, and varicella (to reflect the licensure of MMRV vaccine [measles-mumps-rubella-varicella])

For additional information about the Pink Book and to order the ninth edition online, go to: http://bookstore.phf.org/prod463.htm You can also order by calling (877) 252-1200.
--------------------------------------------------------------

Return to top

(8 of 9)
December 2, 2005
NEW: IAC WEBSITE CONSOLIDATES ANSWERS TO FAQs ONTO ONE WEB SECTION

[The following is cross posted from the Immunization Action Coalition's "IAC EXPRESS" electronic newsletter, 11/28/05.]

To save you time, and the price of a long-distance phone call, IAC recently gathered answers to questions you ask us most frequently and posted them in one section of its main website.

To access the FAQ section, go to: http://www.immunize.org/faq

You can also access the FAQ section from IAC's homepage by going to http://www.immunize.org and scrolling down the Favorites listing in the left column until you reach the entry for frequently asked questions.
-------------------------------------------------------------

Return to top

(9 of 9)
December 2, 2005
TELECONFERENCE ABOUT IMMUNIZING MIGRANT WORKERS SCHEDULED FOR DECEMBER 13

[The following is cross posted from the Immunization Action Coalition's "IAC EXPRESS" electronic newsletter, 11/28/05.]

The National Immunization Coalition TA [technical assistance] Network has scheduled a teleconference that will focus on immunization outreach to migrant, mobile, and immigrant communities. It will be held at 1:00PM, EDT, December 13.

NOTE: CDC will give updates on the current influenza vaccine supply at the beginning of this teleconference and at the beginning of future teleconferences throughout the influenza season.

The presenter is pediatrician Jennie McLaurin, MD, MPH. Trained in maternal and child health care, Dr. McLaurin has 20 years' experience in migrant health care, including service as an outreach worker, medical director, liaison with AAP, and faculty member for the Health Disparities Collaboratives.

To register for the teleconference, email IZTA@aed.org and put this message in the subject line: "Sign me up for migrant health."

For additional information, or to access earlier programs, go to: http://www.izcoalitionsta.org/confcall.cfm


Nastad
www.nastad.org
nastad@nastad.org
          Hepatitis Prevention Programs
www.hepprograms.org
nastad@nastad.org

444 North Capitol Street, NW Suite 339 Washington D.C. 20001 (202) 434-8090